Loading...
Market
Story
67-Year-Old First in UK to Receive BioNTech's mRNA Lung Cancer Vaccine
Aug 23, 2024, 09:16 AM
A pioneering lung cancer vaccine trial has commenced in the UK, marking a significant milestone in cancer treatment. The trial involves a 67-year-old patient who is the first in the UK to receive this experimental vaccine. This trial is part of a larger, world-first initiative being conducted across seven countries. The vaccine, developed by German company BioNTech, uses mRNA technology to prime the immune system to recognize and combat lung cancer cells. This development comes amid a concerning rise in lung cancer cases among young, non-smokers.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
0-2 countries • 25%
3-5 countries • 25%
6-8 countries • 25%
9 or more countries • 25%
Hold Lifted • 33%
Hold Extended • 33%
New Restrictions • 34%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
